Medicenna Therapeutics Corp. Stock price

Equities

MDNA

CA58490H1073

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
1.86 CAD +10.39% Intraday chart for Medicenna Therapeutics Corp. +18.47% +342.86%
Sales 2024 * - Sales 2025 * 583K 431K Capitalization 130M 95.67M
Net income 2024 * -16M -11.82M Net income 2025 * -19M -14.03M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 222 x
P/E ratio 2024 *
-7.91 x
P/E ratio 2025 *
-7.15 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.73%
More Fundamentals * Assessed data
Dynamic Chart
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting CI
Medicenna Reports Q3 Net Loss $5.0 Million MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022 MT
Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors MT
Medicenna Brief: Announcing First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors MT
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors CI
Medicenna Commences Enrollment in ABILITY-1 Study Combining MDNA11 with Pembrolizumab MT
Medicenna Brief: Commencing Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab MT
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab CI
Medicenna Therapeutics Extends Period to Exercise Certain Warrants; Down 1.2% MT
Medicenna Therapeutics Extends Period to Exercise Certain Warrants MT
Medicenna Brief: Announcing Trading on the OTCQB Under the Symbol MDNAF MT
Medicenna Announces "Compelling" Survival Benefit From Phase 2b Study in Recurrent Glioblastoma at NeuroOncology Meeting MT
More news

Latest transcript on Medicenna Therapeutics Corp.

1 day+10.39%
1 week+18.47%
Current month+66.07%
1 month+52.46%
3 months+353.66%
6 months+389.47%
Current year+342.86%
More quotes
1 week
1.45
Extreme 1.45
2.10
1 month
1.05
Extreme 1.05
2.10
Current year
0.40
Extreme 0.4
2.10
1 year
0.22
Extreme 0.215
2.10
3 years
0.22
Extreme 0.215
5.44
5 years
0.22
Extreme 0.215
7.25
10 years
0.22
Extreme 0.215
7.25
More quotes
Managers TitleAgeSince
Founder - 11-09-30
Chief Executive Officer - 15-02-01
Director of Finance/CFO - Feb. 13
Members of the board TitleAgeSince
Director/Board Member 72 19-09-23
Director/Board Member - 16-11-21
Chief Executive Officer - 15-02-01
More insiders
Date Price Change Volume
24-03-28 1.86 +10.39% 452,703
24-03-27 1.685 +8.71% 63,799
24-03-26 1.55 +3.33% 106,586
24-03-25 1.5 -5.06% 92,699
24-03-22 1.58 +0.64% 84,918

Delayed Quote Toronto S.E., March 28, 2024 at 03:59 pm EDT

More quotes
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.86 CAD
Average target price
9 CAD
Spread / Average Target
+383.87%
Consensus
  1. Stock
  2. Equities
  3. Stock Medicenna Therapeutics Corp. - Toronto S.E.